Shorter, safer TB treatment on the horizon? new study tests linezolid dosing
NCT ID NCT05007821
First seen May 03, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study tested two different doses of the drug linezolid, combined with three other medicines, to treat drug-resistant tuberculosis (TB). The goal was to see if a lower dose could work just as well but with fewer side effects. 138 adults with drug-resistant TB took part. The results help doctors find a better, shorter treatment that people can tolerate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barranco CRS (Site ID: 11301)
Lima, 15063, Peru
-
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784)
Chiang Mai, 50200, Thailand
-
De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC) (Site ID: 31981)
Cavite, 4114, Philippines
-
Durban International CRS (Site ID: 11201)
Durban, KwaZulu-Natal, 4052, South Africa
-
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS (Site ID: 31730)
Port-au-Prince, HT-6110, Haiti
-
Gaborone CRS (Site ID: 12701)
Gaborone, South-East District, Botswana
-
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101)
Rio de Janeiro, 21040-360, Brazil
-
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS (Site ID: 30022)
Port-au-Prince, HT-6110, Haiti
-
Rustenburg CRS (Site ID: 31684)
Rustenburg, North West, 0300, South Africa
-
South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site ID: 31793)
Cape Town, Western Cape, 7705, South Africa
-
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802)
Pathum Wan, Bangkok, 10330, Thailand
-
University of Cape Town Lung Institute (UCTLI) CRS (Site ID: 31792)
Cape Town, Western Cape, 7700, South Africa
-
Wits Helen Joseph Hospital CRS (Wits HJH CRS) (Site ID: 11101)
Johannesburg, Gauteng, 2092, South Africa
Conditions
Explore the condition pages connected to this study.